福萊特(601865.SH):擬定增募資不超60億元 用於年產195萬噸新能源裝備用高透面板製造項目等
格隆匯6月1日丨福萊特(601865.SH)公佈2022年度非公開發行A股股票預案,上市公司此次非公開發行A股股票數量計劃不超過此次非公開發行前上市公司A股總股本的30%,即不超過5.09億股(含本數),並以中國證監會的核準文件為準。
此次非公開發行A股股票募集資金總額不超過60億元(含本數),募集資金扣除相關發行費用後將用於投資年產195萬噸新能源裝備用高透面板製造項目、年產150萬噸新能源裝備用超薄超高透面板製造項目及補充流動資金項目等。

注:“年產150萬噸新能源裝備用超薄超高透面板製造項目”將分期實施,此次募投項目投資用於該項目一期建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.